180 related articles for article (PubMed ID: 31419928)
21. Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation.
Qi H; Lu J; Li J; Wang M; Xu Y; Wang Y; Zhang H
J Pharm Sci; 2016 Sep; 105(9):2966-2973. PubMed ID: 26994559
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.
Wu W; Sigmond J; Peters GJ; Borch RF
J Med Chem; 2007 Jul; 50(15):3743-6. PubMed ID: 17602464
[TBL] [Abstract][Full Text] [Related]
23. Biomimetic nanoassemblies of 1-O-octodecyl-2-conjugated linoleoyl-sn-glycero-3-phosphatidyl gemcitabine with phospholipase A
Zuo J; Tong L; Du L; Yang M; Jin Y
Colloids Surf B Biointerfaces; 2017 Apr; 152():467-474. PubMed ID: 28187380
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine: a critical nucleoside for cancer therapy.
Gesto DS; Cerqueira NM; Fernandes PA; Ramos MJ
Curr Med Chem; 2012; 19(7):1076-87. PubMed ID: 22257063
[TBL] [Abstract][Full Text] [Related]
25. Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action.
Derissen EJB; Beijnen JH
Clin Pharmacokinet; 2020 Dec; 59(12):1521-1550. PubMed ID: 33064276
[TBL] [Abstract][Full Text] [Related]
26. Enhanced cellular uptake and intracellular drug controlled release of VESylated gemcitabine prodrug nanocapsules.
Fang Y; Du F; Xu Y; Meng H; Huang J; Zhang X; Lu W; Liu S; Yu J
Colloids Surf B Biointerfaces; 2015 Apr; 128():357-362. PubMed ID: 25746328
[TBL] [Abstract][Full Text] [Related]
27. Chemo-radiotherapy: radiosensitizing nucleoside analogues (review).
Gregoire V; Hittelman WN; Rosier JF; Milas L
Oncol Rep; 1999; 6(5):949-57. PubMed ID: 10425285
[TBL] [Abstract][Full Text] [Related]
28. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
Lee JT; Campbell DO; Satyamurthy N; Czernin J; Radu CG
J Nucl Med; 2012 Feb; 53(2):275-80. PubMed ID: 22302964
[TBL] [Abstract][Full Text] [Related]
29. Development of bioactive gemcitabine-D-Lys
Sayyad N; Vrettos EI; Karampelas T; Chatzigiannis CM; Spyridaki K; Liapakis G; Tamvakopoulos C; Tzakos AG
Eur J Med Chem; 2019 Mar; 166():256-266. PubMed ID: 30716713
[TBL] [Abstract][Full Text] [Related]
30. Role of gemcitabine in cancer therapy.
Toschi L; Finocchiaro G; Bartolini S; Gioia V; Cappuzzo F
Future Oncol; 2005 Feb; 1(1):7-17. PubMed ID: 16555971
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine Lipid Prodrugs: The Key Role of the Lipid Moiety on the Self-Assembly into Nanoparticles.
Coppens E; Desmaële D; Mougin J; Tusseau-Nenez S; Couvreur P; Mura S
Bioconjug Chem; 2021 Apr; 32(4):782-793. PubMed ID: 33797231
[TBL] [Abstract][Full Text] [Related]
32. Interaction of a new anticancer prodrug, gemcitabine-squalene, with a model membrane: coupled DSC and XRD study.
Pili B; Bourgaux C; Amenitsch H; Keller G; Lepêtre-Mouelhi S; Desmaële D; Couvreur P; Ollivon M
Biochim Biophys Acta; 2010 Aug; 1798(8):1522-32. PubMed ID: 20435013
[TBL] [Abstract][Full Text] [Related]
33. Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation.
Pili B; Reddy LH; Bourgaux C; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
Nanoscale; 2010 Aug; 2(8):1521-6. PubMed ID: 20820745
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine.
Dubey RD; Saneja A; Gupta PK; Gupta PN
Eur J Pharm Sci; 2016 Oct; 93():147-62. PubMed ID: 27531553
[TBL] [Abstract][Full Text] [Related]
35. IMP-GMP specific cytosolic 5'-nucleotidase regulates nucleotide pool and prodrug metabolism.
Cividini F; Filoni DN; Pesi R; Allegrini S; Camici M; Tozzi MG
Biochim Biophys Acta; 2015 Jul; 1850(7):1354-61. PubMed ID: 25857773
[TBL] [Abstract][Full Text] [Related]
36. Nanomized tumor-microenvironment-active NIR fluorescent prodrug for ensuring synchronous occurrences of drug release and fluorescence tracing.
Li Q; Cao J; Wang Q; Zhang J; Zhu S; Guo Z; Zhu WH
J Mater Chem B; 2019 Mar; 7(9):1503-1509. PubMed ID: 32255021
[TBL] [Abstract][Full Text] [Related]
37. CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy.
Guo B; Wei J; Wang J; Sun Y; Yuan J; Zhong Z; Meng F
Acta Biomater; 2022 Jun; 145():200-209. PubMed ID: 35430336
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.
Rizzuto I; Ghazaly E; Peters GJ
Pharmacogenomics; 2017 Jun; 18(9):911-925. PubMed ID: 28594276
[TBL] [Abstract][Full Text] [Related]
39. A facile di-acid mono-amidation strategy to prepare cyclization-activating mono-carboxylate transporter 1-targeting gemcitabine prodrugs for enhanced oral delivery.
Wang Y; Wang G; Chen H; Sun Y; Sun M; Liu X; Jian W; He Z; Sun J
Int J Pharm; 2020 Jan; 573():118718. PubMed ID: 31756441
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications.
Moysan E; Bastiat G; Benoit JP
Mol Pharm; 2013 Feb; 10(2):430-44. PubMed ID: 22978251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
